heart blocks 1, 2, 3 - Nursing Case Study
Pathophysiology
• Primary mechanism: In first-degree heart block, there is a delay in conduction through the AV node, often due to increased vagal tone or medications like beta-blockers, leading to prolonged PR interval.
• Secondary mechanism: In second-degree heart block, intermittent failure of conduction occurs at the AV node or His-Purkinje system, classified as Mobitz Type I (Wenckebach, progressive PR lengthening) or Type II (sudden dropped beats without PR change), often due to structural heart disease.
• Primary mechanism: In third-degree heart block, there is a complete block of impulse conduction at the AV node, resulting in atria and ventricles beating independently, often due to advanced age or ischemic heart disease.
• Key complication: Third-degree heart block can lead to severe bradycardia and reduced cardiac output, necessitating possible pacemaker insertion for symptom management and preventing complications like syncope.
Patient Profile
Demographics:
65-year-old male, retired electrician
History:
• Key past medical history: Hypertension, Type 2 Diabetes, Hyperlipidemia
• Current medications: Lisinopril, Metformin, Atorvastatin, Aspirin
• Allergies: Penicillin
Current Presentation:
• Chief complaint: Episodes of dizziness and fatigue
• Key symptoms: Intermittent palpitations, shortness of breath, mild chest discomfort
• Vital signs: Blood Pressure 145/90 mmHg, Heart Rate 50 bpm, Respiratory Rate 22 breaths/min, Temperature 98.6°F, Oxygen Saturation 92% on room air
Section 1
As the medical team continued to monitor the patient, his condition began to evolve, prompting a new round of diagnostic tests. An electrocardiogram (ECG) was conducted to further investigate the suspected heart block. The results confirmed a progression from first-degree to second-degree Mobitz Type II heart block, characterized by sudden dropped QRS complexes without prior PR interval prolongation. This finding was significant as Mobitz Type II heart block is more likely to progress to complete heart block, posing a higher risk for the patient due to potential for severe bradycardia and compromised cardiac output.
Further lab results revealed elevated cardiac enzymes, suggestive of myocardial ischemia, raising concerns about potential underlying coronary artery disease contributing to the conduction abnormalities. Additionally, a transthoracic echocardiogram showed mild left ventricular hypertrophy, a common consequence of the patient's longstanding hypertension and possible contributor to the electrical conduction disturbances.
Given these developments, the medical team faced a critical decision-making point. The presence of a Mobitz Type II block and elevated cardiac enzymes necessitated a consideration for more aggressive intervention, such as the insertion of a temporary pacemaker, to prevent progression to complete heart block and mitigate the risk of syncope or cardiac arrest. This decision required careful weighing of the risks and benefits, along with close monitoring of the patient's hemodynamic status and readiness to respond to any acute changes in his condition.
Section 2
The medical team decided to proceed with the insertion of a temporary pacemaker, aiming to stabilize the patient's heart rhythm and prevent progression to complete heart block. Following the procedure, initial assessment findings indicated a moderate improvement in his heart rate, which stabilized at around 60 beats per minute. Blood pressure readings showed a slight improvement, now averaging 130/80 mmHg. Despite these positive indicators, the nursing staff noted that the patient continued to experience intermittent episodes of dizziness and mild shortness of breath, symptoms that warranted further investigation to rule out any additional complications.
Subsequent diagnostic testing, including a repeat ECG, showed a reduction in the frequency of dropped QRS complexes, suggesting that the pacemaker was effectively mitigating the risk of severe bradycardia. However, the patient's lab results revealed a concerning trend: his troponin levels, which initially indicated myocardial ischemia, had not decreased as expected, suggesting ongoing cardiac stress. The patient's renal function tests also showed a slight elevation in creatinine levels, pointing to the possibility of acute kidney injury, potentially exacerbated by hypotension episodes prior to pacemaker insertion.
These findings prompted the team to consider the need for additional interventions, such as optimizing the patient's medication regimen to address both his potential coronary artery disease and hypertension. The development of mild acute kidney injury added another layer of complexity, highlighting the need for careful fluid management and consideration of nephrotoxic medication adjustments. The team prepared to conduct a coronary angiography to evaluate the extent of any coronary blockages, ensuring that they could address both the electrical and ischemic components of the patient’s condition comprehensively. As the team deliberated, they remained vigilant for any signs of further deterioration, ready to adapt their approach as the patient's response to treatment unfolded.
Section 3
Following the decision to conduct a coronary angiography, the medical team closely monitored the patient's response. The procedure revealed a significant stenosis in the left anterior descending artery, which was promptly addressed with the placement of a drug-eluting stent. Post-procedure, the patient's heart rate remained stable at 62 beats per minute, and his blood pressure improved further to an average of 135/85 mmHg. Despite these improvements, the patient continued to report episodes of mild shortness of breath, particularly with exertion, prompting additional assessments to rule out any complications from the angiography or pacemaker insertion.
New diagnostic results included a follow-up ECG, which showed normal sinus rhythm with consistent pacing spikes, affirming the pacemaker's effective functioning. However, the patient's echocardiogram indicated a mild reduction in ejection fraction, dropping from 55% pre-procedure to 50%, raising concerns about potential left ventricular dysfunction. Concurrently, repeat lab tests showed persistent elevation in creatinine at 1.9 mg/dL, despite efforts to optimize fluid balance, suggesting unresolved renal impairment. The team considered the potential impact of contrast-induced nephropathy from the recent angiography, necessitating adjustments in the patient's diuretic regimen and increased monitoring of renal function.
In response to these findings, the clinical team initiated a comprehensive management plan, including titration of heart failure medications such as ACE inhibitors and beta-blockers, aiming to support cardiac function while minimizing further renal insult. Nutritional consultation was also sought to optimize the patient's diet, focusing on low-sodium and renal-friendly options to assist in managing his complex condition. As they proceeded with this multifaceted approach, the team remained attentive to the patient's evolving clinical picture, prepared to make necessary modifications should his symptoms or lab results indicate further complications.
Section 4
As the clinical team continued to monitor the patient's progress, new complications began to emerge. Two days post-angiography, the patient experienced an episode of dizziness and palpitations, prompting an immediate reassessment. Upon evaluation, his heart rate was noted to be irregular, fluctuating between 48 and 72 beats per minute. An urgent ECG revealed the development of a second-degree heart block, Mobitz Type II, characterized by intermittent non-conducted P waves and variable PR intervals. This finding indicated a potential progression of his conduction system disease, likely exacerbated by the recent intervention and underlying cardiac pathology.
In response to this new development, the medical team decided to adjust the patient's beta-blocker therapy, carefully balancing the need to control his heart rate while avoiding exacerbation of the heart block. Additionally, the team initiated temporary transcutaneous pacing as a precautionary measure, ensuring that the patient's cardiac output remained stable during periods of bradycardia. The patient's blood pressure remained relatively stable at 130/80 mmHg, but the team remained vigilant for any signs of hemodynamic instability.
Simultaneously, the patient's renal function displayed further decline, with creatinine levels rising to 2.2 mg/dL. This prompted an urgent nephrology consult to evaluate the potential need for renal replacement therapy. The nephrologist recommended further reduction in diuretic use and increased hydration to mitigate the contrast-induced nephropathy. The management plan now included close daily monitoring of renal markers and fluid status, alongside cardiac rhythm surveillance, to address the evolving complexities of the patient's condition. The team remained committed to a dynamic and integrated approach, poised to adapt their strategies based on the patient's ongoing clinical response.
Section 5
Despite the initial stabilization efforts, the patient’s condition underwent further changes, necessitating a reassessment of both cardiac and renal status. Three days post-intervention, the patient exhibited increased fatigue and mild confusion. Vital signs showed a heart rate that had further dropped to an average of 42 beats per minute, with occasional pauses noted on telemetry. Blood pressure remained stable at 128/76 mmHg, though episodes of hypotension were documented during the bradycardic episodes. The ECG now displayed more frequent non-conducted P waves, and occasional wide QRS complexes, suggesting progression towards a third-degree heart block.
In light of these developments, the medical team opted to transition from temporary transcutaneous pacing to a more reliable temporary transvenous pacing to ensure consistent cardiac support, given the worsening conduction delay. The nephrology team also reported an increase in creatinine to 2.8 mg/dL, and a slight drop in urine output, indicating continued renal compromise. The patient was started on a low-dose dopamine infusion to potentially enhance renal perfusion, alongside meticulous adjustment of fluid management to strike a balance between hydration and avoiding fluid overload.
These changes highlighted the complexity of managing concurrent cardiac and renal dysfunction. The team held a multidisciplinary meeting to streamline communication and revise the treatment plan, emphasizing the importance of frequent reassessment and readiness to escalate interventions, including potential permanent pacing and renal replacement therapy, should the patient’s condition not improve. This integrative approach ensured that all potential complications were anticipated, allowing the team to remain proactive in their care strategy as the patient’s status continued to evolve.